After-Hours Stock Movers 07/19 (PTCT) (CE) (ISRG) Higher; (SKX) (ZYNE) (FTD) Lower (more...)
- Pre-Fed jitters keep S&P 500, Nasdaq below record highs
- Oracle (ORCL) Tops Profit and Sales Views But Stock Falls on Guidance Miss, Analysts Still Raise PTs
- General Motors (GM) to Boost EV and AV Investments to $35 Billion Through 2025
- Oil nears $75 as demand rises, U.S. refiners boost output
- Roblox (RBLX) Lower as DAUs Fall Sequentially
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Skechers USA (NYSE: SKX) 26.8% LOWER; reported Q2 EPS of $0.29, $0.12 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.13 billion.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) 18.4% LOWER; intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.
FTD Companies, Inc. (Nasdaq: FTD) 17% LOWER; announced that its Board of Directors has initiated a review of strategic alternatives focused on maximizing stockholder value. The strategic alternatives expected to be considered include, but are not limited to, a sale or merger of the Company, FTD continuing to pursue value-enhancing initiatives as a standalone company, a capital structure optimization that may involve potential financings, or the sale or other disposition of certain of the Companys businesses or assets. FTD has retained Moelis & Company LLC as financial advisor to assist with its strategic alternatives review. The FTD Board of Directors also announced that it has appointed Scott D. Levin, currently FTDs Executive Vice President, General Counsel and Secretary, as interim President and Chief Executive Officer. Mr. Levin succeeds John C. Walden, who has stepped down from these positions and from FTD's board of directors, effective immediately.
PTC Therapeutics, Inc. (NASDAQ: PTCT) 7.8% HIGHER; entered into an agreement to acquire Agilis Biotherapeutics, Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). The transaction was approved by the Boards of both companies.
Celanese Corp. (NYSE: CE) 5.9% HIGHER; reported Q2 EPS of $2.90, $0.45 better than the analyst estimate of $2.45. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.81 billion. Celanese Corp. sees FY2018 EPS of $10.50-$10.75, versus the consensus of $9.64.
Intuitive Surgical (NASDAQ: ISRG) 4.2% HIGHER; reported Q2 EPS of $2.76, $0.26 better than the analyst estimate of $2.50. Revenue for the quarter came in at $909 million versus the consensus estimate of $877.56 million.
Skyworks Solutions (NASDAQ: SWKS) 3.5% HIGHER; reported Q3 EPS of $1.64, $0.04 better than the analyst estimate of $1.60. Revenue for the quarter came in at $894.3 million versus the consensus estimate of $889.05 million.
Capital One Financial (NYSE: COF) 2% LOWER; reported Q2 EPS of $3.22, $0.59 better than the analyst estimate of $2.63. Revenue for the quarter came in at $7.2 billion versus the consensus estimate of $6.95 billion.
Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) 1.4% LOWER; announced today that it is proposing to offer its common shares in an underwritten public offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- At Home Group (HOME), Hellman & Friedman Amend Definitive Agreement to Increase Offer Price to $37 Per Share
- Creatd (CRTD) to Purchase a Majority Stake in Influencer Talent Management Firm, WHE Agency
- QualTek to Go Public in Merger with Roth CH Acquisition III Co. (ROCR)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesAfter-Hours Movers, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!